OBJECTIVE: In patients with heart failure (HF), Cheyne-Stokes respiration (CSR) is characterized by chronic hyperventilation (HV) with low arterial partial pressure of carbon dioxide (pCO2). It is still unclear whether this HV represents a compensatory response to HF or an independent comorbidity. This study investigated the hemodynamic effects of HV in HF patients and volunteers. METHODS: A total of 15 volunteers [13 male, 25 ± 4 years, brain natriuretic peptide (BNP) <49 pg/mL, left ventricular rejection fraction (LVEF) >55 %) and 20 HF patients with reduced LVEF (15 male, 67.7 ± 12 years, NYHA class 2.6 ± 0.6, BNP 790 ± 818 pg/mL, LVEF 32.4 ± 7.3 %) were enrolled. Hemodynamics was monitored noninvasively in volunteers (TaskForce Monitor, CNSystems) and invasively in HF patients. RESULTS: During HV, the transcutaneous CO2 pressure in volunteers decreased from 38.7 ± 2.5 to 28.6 ± 3.3 mmHg (p < 0.001) and pCO2 in HF patients decreased from 33.6 ± 3.7 to 22.2 ± 3.2 mmHg (p < 0.001). There was a significant increase in cardiac output (CO) in both volunteers (6.2 ± 1.3-7.5 ± 1.3 L/min, p < 0.001) and HF patients (4.4 ± 1.3-5.0 ± 1.3 L/min), mainly as a result of an increase in heart rate (67.4 ± 7.6-82.8 ± 10.9/min, p < 0.001; and 77.2 ± 17.7-86.2 ± 22.4/min, p < 0.001, respectively); stroke volume (SV) was unchanged in volunteers (93.7 ± 19.6-93.8 ± 21.4 mL) and only slightly increased in HF patients (64.4 ± 28.7-68.5 ± 23.2 mL). CONCLUSIONS: CSR with associated HV may be a compensatory mechanism in patients with a failing heart. This compensatory mechanism includes an increase in heart rate, which might be deleterious in the long run.
OBJECTIVE: In patients with heart failure (HF), Cheyne-Stokes respiration (CSR) is characterized by chronic hyperventilation (HV) with low arterial partial pressure of carbon dioxide (pCO2). It is still unclear whether this HV represents a compensatory response to HF or an independent comorbidity. This study investigated the hemodynamic effects of HV in HF patients and volunteers. METHODS: A total of 15 volunteers [13 male, 25 ± 4 years, brain natriuretic peptide (BNP) <49 pg/mL, left ventricular rejection fraction (LVEF) >55 %) and 20 HF patients with reduced LVEF (15 male, 67.7 ± 12 years, NYHA class 2.6 ± 0.6, BNP 790 ± 818 pg/mL, LVEF 32.4 ± 7.3 %) were enrolled. Hemodynamics was monitored noninvasively in volunteers (TaskForce Monitor, CNSystems) and invasively in HF patients. RESULTS: During HV, the transcutaneous CO2 pressure in volunteers decreased from 38.7 ± 2.5 to 28.6 ± 3.3 mmHg (p < 0.001) and pCO2 in HF patients decreased from 33.6 ± 3.7 to 22.2 ± 3.2 mmHg (p < 0.001). There was a significant increase in cardiac output (CO) in both volunteers (6.2 ± 1.3-7.5 ± 1.3 L/min, p < 0.001) and HF patients (4.4 ± 1.3-5.0 ± 1.3 L/min), mainly as a result of an increase in heart rate (67.4 ± 7.6-82.8 ± 10.9/min, p < 0.001; and 77.2 ± 17.7-86.2 ± 22.4/min, p < 0.001, respectively); stroke volume (SV) was unchanged in volunteers (93.7 ± 19.6-93.8 ± 21.4 mL) and only slightly increased in HF patients (64.4 ± 28.7-68.5 ± 23.2 mL). CONCLUSIONS: CSR with associated HV may be a compensatory mechanism in patients with a failing heart. This compensatory mechanism includes an increase in heart rate, which might be deleterious in the long run.
Authors: Olaf Oldenburg; Thomas Bitter; Marcus Wiemer; Christoph Langer; Dieter Horstkotte; Cornelia Piper Journal: Sleep Med Date: 2009-01-08 Impact factor: 3.492
Authors: Justin C T Pepperell; Nick A Maskell; David R Jones; Beverley A Langford-Wiley; Nicky Crosthwaite; John R Stradling; Robert J O Davies Journal: Am J Respir Crit Care Med Date: 2003-08-19 Impact factor: 21.405
Authors: Dominik Linz; Holger Woehrle; Thomas Bitter; Henrik Fox; Martin R Cowie; Michael Böhm; Olaf Oldenburg Journal: Clin Res Cardiol Date: 2015-04-23 Impact factor: 5.460
Authors: Dominik Linz; Henrik Fox; Thomas Bitter; Jens Spießhöfer; Christoph Schöbel; Erik Skobel; Anke Türoff; Michael Böhm; Martin R Cowie; Michael Arzt; Olaf Oldenburg Journal: Clin Res Cardiol Date: 2016-02-12 Impact factor: 5.460
Authors: Sebastian Roth; Henrik Fox; Uwe Fuchs; Uwe Schulz; Angelika Costard-Jäckle; Jan F Gummert; Dieter Horstkotte; Olaf Oldenburg; Thomas Bitter Journal: Clin Res Cardiol Date: 2018-01-19 Impact factor: 5.460
Authors: Katharina Heider; Michael Arzt; Christoph Lerzer; Leonie Kolb; Michael Pfeifer; Lars S Maier; Florian Gfüllner; Maximilian Valentin Malfertheiner Journal: Clin Res Cardiol Date: 2018-01-25 Impact factor: 5.460
Authors: Anna Kazimierczak; Paweł Krzesiński; Grzegorz Gielerak; Beata Uziębło-Życzkowska; Paweł Smurzyński; Robert Ryczek; Andrzej Cwetsch; Andrzej Skrobowski Journal: Med Sci Monit Date: 2016-08-25
Authors: D Müller; A Remppis; P Schauerte; S Schmidt-Schweda; D Burkhoff; B Rousso; D Gutterman; J Senges; G Hindricks; K-H Kuck Journal: Clin Res Cardiol Date: 2017-07-06 Impact factor: 5.460